TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovar... اقرأ أكثر
احصل على تحليلات مفصلة للأسهم من LSEG تتضمن السعر المستهدف بحسب رأي المحللين.